---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024487"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:27:37.375967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Genprex issues 2025 corporate update; two lung cancer trials ongoing

## Summary
- Patient treatment continues in two lung cancer clinical trials.
- Company highlights clinical milestones across oncology and diabetes programs.
- CEO Ryan Confer cites progress and upcoming milestones for H2 2025 and beyond.
- No specific financial results or enrollment numbers disclosed.

## SEC filing metadata
- accession: 0001437749-25-024487
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/0001437749-25-024487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/gnpx20250618d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024487
- JSON: https://secwatch.observer/filing/0001437749-25-024487.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.